Literature DB >> 22875158

Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.

Andrea Romano1, L F Calabria, F Tavanti, G Minniti, M C Rossi-Espagnet, V Coppola, S Pugliese, D Guida, G Francione, C Colonnese, L M Fantozzi, A Bozzao.   

Abstract

OBJECTIVE: To evaluate whether apparent diffusion coefficient (ADC) values can predict the status of MGMT of glioblastoma multiforme (GBM) and correlate with overall survival (OS) and progression-free survival (PFS).
METHODS: This retrospective study included 47 patients with pathologically proven glioblastoma. All of them underwent MR DWI study before surgery (mean time 1 week) and the status of methylguanine-DNA-methyltransferase (MGMT) promoter methylation was searched for. Minimum apparent diffusion coefficient (ADC) values were evaluated. OS and PSF parameters were calculated, and Student's t-test, Kaplan-Meier curves, linear and Cox regression were performed.
RESULTS: Twenty-five patients showed positive methylation of the MGMT promoter. Patients showing MGMT promoter methylation had higher minimum ADC values, and they survived longer than those without MGMT promoter methylation. The median ADCmin value of 0.80 represents the cutoff value able to distinguish between methylated and un-methylated patients. Patients showing minimum ADC values higher than 0.80 survived longer than patients with minimum ADC values lower than 0.80. A linear correlation between minimum ADC values vs. the OS and PFS was observed.
CONCLUSIONS: Minimum ADC values in glioblastoma multiforme could be used as a preoperative parameter to estimate the status of MGMT promoter methylation and the survival of patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875158     DOI: 10.1007/s00330-012-2601-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  33 in total

1.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

2.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 3.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Authors:  Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi
Journal:  Nat Rev Neurol       Date:  2009-12-08       Impact factor: 42.937

4.  Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma.

Authors:  R K Gupta; T F Cloughesy; U Sinha; J Garakian; J Lazareff; G Rubino; L Rubino; D P Becker; H V Vinters; J R Alger
Journal:  J Neurooncol       Date:  2000-12       Impact factor: 4.130

5.  Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.

Authors:  Ryuji Murakami; Takeshi Sugahara; Hideo Nakamura; Toshinori Hirai; Mika Kitajima; Yoshiko Hayashida; Yuji Baba; Natsuo Oya; Jun-Ichi Kuratsu; Yasuyuki Yamashita
Journal:  Radiology       Date:  2007-03-13       Impact factor: 11.105

6.  Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.

Authors:  Marica Eoli; Francesca Menghi; Maria Grazia Bruzzone; Tiziana De Simone; Lorella Valletta; Bianca Pollo; Lorena Bissola; Antonio Silvani; Donatella Bianchessi; Ludovico D'Incerti; Graziella Filippini; Giovanni Broggi; Amerigo Boiardi; Gaetano Finocchiaro
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

7.  CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

Authors:  Maria F Paz; Ricard Yaya-Tur; Iñigo Rojas-Marcos; Gaspar Reynes; Marina Pollan; Lucinda Aguirre-Cruz; Jose Luis García-Lopez; Jose Piquer; María-Jose Safont; Carmen Balaña; Montserrat Sanchez-Cespedes; Mercedes García-Villanueva; Leoncio Arribas; Manel Esteller
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

8.  Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Authors:  Joonmi Oh; Roland G Henry; Andrea Pirzkall; Ying Lu; Xiaojuan Li; Isabelle Catalaa; Susan Chang; William P Dillon; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2004-05       Impact factor: 4.813

Review 9.  Molecular genetic markers as predictors of response to chemotherapy in gliomas.

Authors:  Ahmed Idbaih; Antonio Omuro; François Ducray; Khê Hoang-Xuan
Journal:  Curr Opin Oncol       Date:  2007-11       Impact factor: 3.645

Review 10.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

View more
  38 in total

1.  Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.

Authors:  Katerina Deike; Benedikt Wiestler; Markus Graf; Caroline Reimer; Ralf O Floca; Philipp Bäumer; Philipp Kickingereder; Sabine Heiland; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

2.  Prognostic paradox: brain damage around the glioblastoma resection cavity.

Authors:  Takuya Furuta; Mitsutoshi Nakada; Fumiaki Ueda; Takuya Watanabe; Yasuaki Arakawa; Ryo Higashi; Masaaki Hashimoto; Hisashi Nitta; Yutaka Hayashi; Jun-ichiro Hamada
Journal:  J Neurooncol       Date:  2014-03-07       Impact factor: 4.130

3.  Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.

Authors:  Shanshan Jiang; Qihong Rui; Yu Wang; Hye-Young Heo; Tianyu Zou; Hao Yu; Yi Zhang; Xianlong Wang; Yongxing Du; Xinrui Wen; Fangyao Chen; Jihong Wang; Charles G Eberhart; Jinyuan Zhou; Zhibo Wen
Journal:  Eur Radiol       Date:  2017-12-12       Impact factor: 5.315

Review 4.  Assessment and treatment relevance in elderly glioblastoma patients.

Authors:  Luc Bauchet; Sonia Zouaoui; Amélie Darlix; Nicolas Menjot de Champfleur; Ernestine Ferreira; Michel Fabbro; Christine Kerr; Luc Taillandier
Journal:  Neuro Oncol       Date:  2014-05-02       Impact factor: 12.300

Review 5.  Imaging genomics in cancer research: limitations and promises.

Authors:  Harrison X Bai; Ashley M Lee; Li Yang; Paul Zhang; Christos Davatzikos; John M Maris; Sharon J Diskin
Journal:  Br J Radiol       Date:  2016-02-11       Impact factor: 3.039

6.  Increasing FLAIR signal intensity in the postoperative cavity predicts progression in gross-total resected high-grade gliomas.

Authors:  Guan-Min Quan; Yong-Li Zheng; Tao Yuan; Jian-Ming Lei
Journal:  J Neurooncol       Date:  2018-03-21       Impact factor: 4.130

7.  Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.

Authors:  Yi Cui; Shangjie Ren; Khin Khin Tha; Jia Wu; Hiroki Shirato; Ruijiang Li
Journal:  Eur Radiol       Date:  2017-02-06       Impact factor: 5.315

8.  Choline-to-N-acetyl aspartate and lipids-lactate-to-creatine ratios together with age assemble a significant Cox's proportional-hazards regression model for prediction of survival in high-grade gliomas.

Authors:  Ernesto Roldan-Valadez; Camilo Rios; Daniel Motola-Kuba; Juan Matus-Santos; Antonio R Villa; Sergio Moreno-Jimenez
Journal:  Br J Radiol       Date:  2016-09-14       Impact factor: 3.039

9.  Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.

Authors:  Lindsay S Rowe; John A Butman; Megan Mackey; Joanna H Shih; Theresa Cooley-Zgela; Holly Ning; Mark R Gilbert; DeeDee K Smart; Kevin Camphausen; Andra V Krauze
Journal:  J Neurooncol       Date:  2018-05-16       Impact factor: 4.130

Review 10.  Emerging methods for disease monitoring in malignant gliomas.

Authors:  Prakash Ambady; Chetan Bettegowda; Matthias Holdhoff
Journal:  CNS Oncol       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.